AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1V. Malaria to Measles, Imported

NNDSS - TABLE 1V. Malaria to Measles, Imported - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Notice:  The total numbers of measles cases in Table 1v for weeks 1-51 in the 2019 data are correct but counts for imported and indigenous categories are incorrect. Measles data for week 52 (in Table 1v) were updated on 02-28-2020 to correct the classification of imported and indigenous. Please see week 52, 2019 data for the correct breakout of imported and indigenous measles cases.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).

§ Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired.
Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report

Background
          Mucormycosis (or zygomycosis) is the term for infection caused by fungi of the order Mucorales. Mucoraceae may produce severe disease in susceptible individuals, notably patients with diabetes and leukemia. Rhinocerebral mucormycosis most commonly manifests itself in the setting of poorly controlled diabetes, especially with ketoacidosis.
        
        
          Case Presentation
          A 31-year-old diabetic man presented to the outpatient clinic with the following signs and symptoms: headache, periorbital pain, swelling and loss of vision in the right eye. On physical examination his right eye was red and swollen. There was periorbital cellulitis and the conjunctiva was edematous. KOH preparation of purulent discharge showed broad, ribbonlike, aseptate hyphae when examined under a fluorescence microscope. Cranial MRI showed involvement of the right orbit, thrombosis in cavernous sinus and infiltrates at ethmoid and maxillary sinuses. Mucormycosis was diagnosed based on these findings. Amphotericin B (AmBisome®; 2 mg/kg.d) was initiated after the test doses. Right orbitectomy and right partial maxillectomy were performed; the lesions in ethmoid and maxillary sinuses were removed. The duration of the liposomal amphotericin B therapy was approximately 6 months and the total dose of liposomal amphotericin B used was 32 grams. Liposomal amphotericin B therapy was stopped six months later and oral fluconazole was started.
        
        
          Conclusions
          Although a total surgical debridement of the lesions could not be performed, it is remarkable that regression of the disease could be achieved with medical therapy alone.
Child and Adult Care Food Program Participation

The Child and Adult Care Food Program (CACFP) is a nutrition education and meal reimbursement program helping providers serve nutritious and safely prepared meals and snacks to children and adults in day care settings. This dataset includes the names and locations of participating day care sites and whether or not the site is Breastfeeding Friendly Certified with CACFP, participating in the Eat Well Play Hard in Child Care Settings (EWPHCCS) project, or participating in the Eat Well Play Hard in Day Care Homes (EWPHDCH) project.   This dataset excludes Child and Adult Care Food Program participation provided at homeless shelters and legally-exempt day care home providers.  

Not all counties in NYS are serviced by the grantees implementing the project EWPHCSS. 

The EWPHDCH project is currently limited to the areas served by the contracted agencies. 

The Child and Adult Care Food Program dataset is related to the Child Care Related Programs dataset on the www.Open.ny.gov website, however this dataset includes additional nutrition information.  The Office of Children and Family Services (OCFS) is currently working to update the Child Care Related Programs dataset on a more frequent schedule with the OPEN NY team.  OCFS and DOH will then be able to synchronize in the near future.  Temporarily, DOH has omitted addresses for regulated child care providers that provide home care since this information is available on www.Open.ny.gov by using this link: https://data.ny.gov/Human-Services/Child-Care-Regulated-Programs/cb42-qumz.   

For more information, please visit http://www.health.ny.gov/prevention/nutrition/cacfp/. The "About" tab contains additional details concerning this dataset.
Indicators for 2024B

The CY 2024 Medicare Physician Fee Schedule has been updated by the annual PFS Final Rule for various new policies and for new and existing CPT/HCPCS codes.  For January 1, 2024, through March 8, 2024, the PFS conversion factor is $32.7442.  For March 9, 2024, through December 31, 2024, the CY 2024 Medicare Physician Fee Schedule has been updated by new legislation that revises the PFS conversion factor to $33.2875.
Table 2. Marijuana Use in the Past Year among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past year marijuana use by those aged 12 or older by State and substate regions.
Naloxone hydrochloride

Naloxone Hydrochloride is an injectable prescription drug that reverses opioid overdoses by blocking opioid effects in the body. Available as a 0.4 mg/mL solution for intramuscular, intravenous, or subcutaneous injection, it's manufactured by Eugia US LLC under application ANDA212456. This information was generated using AI and is provided for informational and research purposes only.
Percentage of Drivers and Front Seat Passengers Wearing Seat Belts, 2012 & 2014, Region 2 - New York

Source for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2014 national data: National Occupant Protection Use Survey (NOPUS), 2014.  Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 state data: Seat Belt Use in 2014- Use Rates in the States and Territories
An Investigation Into the Relationship Between Coal Workers’ Pneumoconiosis and Dust Exposure in U.S. Coal Miners

The National Study of Coal Workers’ Pneumoconiosis (NSCWP) is a large, continuing epidemiologic study of the respiratory health of U.S. coal miners. By using information from the study, prevalence of coal workers’ pneumoconiosis (CWP) was related to indexes of dust exposure obtained from research and compliance sampling data. Clear relationships between prevalences of both simple CWP and progressive massive fibrosis (PMF) and estimated dust exposure were seen. Additional effects independently associated with coal rank (% carbon) and age were also seen. Logistic model fitting indicated that between 2% and 12% of miners exposed to a 2-mg/m3 dust environment in bituminous coal mines would be expected to have Category 2 or greater CWP after a 40-yr working life; PMF would be expected for between 1.3% and 6.7%. The risks for anthracite miners appeared to be greater. There was a suggestion of a background level of abnormality, not associated with dust exposure, but increasing with age. Although there are certain we
Ibuprofen

Children's Ibuprofen Blue Raspberry is an over-the-counter oral suspension with 100 mg of ibuprofen per 5 mL. As a nonsteroidal anti-inflammatory drug, it helps reduce fever and relieve minor aches and pains in children. Available in 120 mL or 240 mL bottles. This information was generated using AI and is provided for informational and research purposes only.
Tribal TANF Work Participation Rates

Reports show work participation rate targets and actual rates achieved for Tribal TANF recipient families, reported by Tribe and fiscal year.

<b>Units of Response: </b>Tribes

<b>Type of Data: </b>Administrative

<b>Tribal Data: </b>Yes

<b>COVID-19 Data: </b>No

<b>Periodicity: </b>Annual

<b>SORN: </b>https://www.federalregister.gov/documents/2015/04/02/2015-07440/privacy-act-of-1974-system-of-records-notice

<b>Data Use Agreement: </b>https://www.icpsr.umich.edu/rpxlogin

<b>Data Use Agreement Location: </b>Not Applicable

<b>Equity Indicators: </b>Indigenous Population

<b>Granularity: </b>Tribe

<b>Spatial: </b>Tribes

<b>Geocoding: </b>Tribe
Patent AT-E399549-T1: [Translated] TREATMENT OF DISEASE CAUSED BY THE LJUNGAN VIRUS BY USING PLECONARIL

A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, such as Myocarditis, Cardiomyopathia, Guillain Barre Syndrome, and Diabetes Mellitus, Multiple Sclerosis, Chronic Fatigue Syndrome, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Dermatomyositis, Polymyositis, Spontaneous Abortion, Intrauterine Death, Preeclampsia, Sudden infant Death Syndrome, Bell's (facial) paralysis, Addison's disease, and Pernicious anemia, is described. An antiviral compound effective against a Ljungan virus, such as a compound effective against a picornavirus, e.g. Pleconaril or a derivative thereof, is used for the preparation of a medicament for the treatment of a disease in a mammal that is caused by a Ljungan virus infection, to eliminate or inhibit proliferation of the virus in the mammal and at the same time prevent and/or treat the disease in the mammal. A composition for treatment of a mammal for a disease caused by Ljungan virus infection including an antiviral compound, antiserum, and an interferon. A method of treatment of a mammal for a disease caused by a Ljungan virus infection.
Compound 526773: 7-Hydroxy-palmitic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 7-[tert-butyl(dimethyl)silyl]oxyhexadecanoate. Molecular Formula: C23H48O3Si. Molecular Weight: 400.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525194: Chloromethyl 2-chlorohexanoate

Chemical compound data from PubChem database. IUPAC Name: chloromethyl 2-chlorohexanoate. Molecular Formula: C7H12Cl2O2. Molecular Weight: 199.07. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401490-T1: [Translated] SELF-ADAPTABLE CEMENT SYSTEMS

A composition for well cementing comprising water, cement and a blend of solid material wherein said material comprises a mixture of at least two additives selected from the list consisting of rubber, poly 2 2 1 bicyclo heptene (polynorbomene), alkylstyrene, crosslinked substituted vinyl acrylate copolymers and diatomaceous earth
NNDSS - TABLE 1D. Arboviral diseases, West Nile virus to Babesiosis

NNDSS - Table 1D. Arboviral diseases, neuroinvasive and non-neuroinvasive, West Nile virus disease to Babesiosis - 2019.In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
NNDSS - Table 1G. Carbapenemase-producing carbapenem-resistant Enterobacteriaceae to Chlamydia trachomatis infection

NNDSS - Table 1G. Carbapenemase-producing carbapenem-resistant Enterobacteriaceae to Chlamydia trachomatis infection - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
2010-2011 State-specific tables of prevalence estimates and estimated totals. Also included are tables for the four census regions and the total U.S

These are tables of State estimates for 25 measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State by age group.
TABLE III. Deaths in 122 U.S. cities

TABLE III. Deaths in 122 U.S. cities - 2015122 Cities Mortality Reporting System ��� Each week, the vital statistics offices of 122 cities across the United States report the total number of death certificates processed and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group (Under 28 days, 28 days ���1 year, 1-14 years, 15-24 years, 25-44 years, 45-64 years, 65-74 years, 75-84 years, and ��� 85 years).FOOTNOTE:U: Unavailable      -: No reported cases * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. ** Totals include unknown ages. *** Partial counts for this city.
NYTD Technical Bulletin #2: Compliance Standards

This TB describes the standards a NYTD data file must meet to comply with the provisions of the NYTD regulation found at 45 CFR 1356.85, including element-by-element details of the error-free information standards states must meet pursuant to 45 CFR 1356.85(a)(3) and 1356.85(b)(1).

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528588: Bis[tert-butyl(dimethyl)silyl] oxalate

Chemical compound data from PubChem database. IUPAC Name: bis[tert-butyl(dimethyl)silyl] oxalate. Molecular Formula: C14H30O4Si2. Molecular Weight: 318.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Runaway and Homeless Youth Management Information System (1996)

It is estimated that over a million young people run away or become homeless each year.  These youth face increasingly complex issues, including substance abuse, physical and sexual abuse, and AIDS.  The serious issues faced by these youths are coupled with funding constraints among almost all agencies providing services to this population.  In 1974 the Family and Youth Services Bureau (FYSB) authorized funding to assist community based programs to serve youth who were not otherwise being served by traditional human service agencies.  The funding was used for the operation of basic center programs which would provide support for runaway and homeless youth (RHY).  The programs offered emergency shelter, crisis intervention services, and family reunification services.   In 1988 the Transitional Living Program was introduced in order to provide services to older youth requiring assistance in becoming self-sufficient.While helping to support at-risk youth, the FYSB laws also mandate that certain data be regularly collected and reported.  For example, FYSB supported agencies must report on the profile of the youth and families they serve, and provide an overview of the services which they deliver under their grant programs.  In order to assist these grantees in their reporting responsibilities, FYSB funded the development of a Runaway and Homeless Youth Management Information System (RHY MIS).  The RHY MIS was designed to provide comprehensive information on youth served, services provided, and programs which provide the services.The RHY MIS was designed, developed, and implemented by Information Technology International (ITI).  Gradual implementation of the MIS began in 1992 with approximately 400 RHY grantee sites across the country.  By 1995, virtually all existing grant programs had at least one staff member who had been trained and grantees were expected to use the MIS and submit data to FYSB on a quarterly basis.The fiscal year 1996 RHY MIS dataset contains data submitted during the federal fiscal year 1996.  Data are included from participating agencies in 53 US States and Territories.  The dataset includes three files. A demographics file contains 72540 observations and 153 variables. Two additional files contain 64100 observations and a combined 235 variables pertaining to youth problems and services provided.

Investigators: Papadopoulos, Helen & Diepenbrock, Elaine
HAICViz - MuGSI

<p>The healthcare-associated infection component of CDC’s <a href="https://www.cdc.gov/ncezid/dpei/eip/index.html" target="_blank">EIP</a> engages a <a href="https://www.cdc.gov/ncezid/dpei/eip/eip-sites.html" target="_blank">network</a> of state health departments and their academic medical center partners to help answer critical questions about emerging HAI threats, advanced infection tracking methods, and antibiotic resistance in the United States. Information gathered through this activity will play a key role in shaping future policies and recommendations targeting HAI prevention. </p>